COVID-19 and Hepatic Injury: Cellular and Molecular Mechanisms in Diverse Liver Cells

Overview

Journal World J Gastroenterol

Publisher Baishideng Publishing Group

Specialty Gastroenterology

Date 2023 Jan 23

PMID 36688024

Authors

Fares E M Ali

Mostafa K Abd El-Aziz

Mahmoud M Ali

Osama M Ghogar

Adel G Bakr

Affiliations

Soon will be listed here.

Abstract

The coronavirus disease 2019 (COVID-19) represents a global health and economic challenge. Hepatic injuries have been approved to be associated with severe acute respiratory syndrome coronavirus (SARS-CoV-2) infection. The viral tropism pattern of SARS-CoV-2 can induce hepatic injuries either by itself or by worsening the conditions of patients with hepatic diseases. Besides, other factors have been reported to play a crucial role in the pathological forms of hepatic injuries induced by SARS-CoV-2, including cytokine storm, hypoxia, endothelial cells, and even some treatments for COVID-19. On the other hand, several groups of people could be at risk of hepatic COVID-19 complications, such as pregnant women and neonates. The present review outlines and discusses the interplay between SARS-CoV-2 infection and hepatic injury, hepatic illness comorbidity, and risk factors. Besides, it is focused on the vaccination process and the role of developed vaccines in preventing hepatic injuries due to SARS-CoV-2 infection.

Citing Articles

Pancytopenia and Acute Liver Failure Caused by Mild COVID-19 in an Older Patient: A Case Report.

Tanaka I, Sato Y, Sano C, Ohta R Cureus. 2024; 16(10):e72681.

PMID: 39618622 PMC: 11605485. DOI: 10.7759/cureus.72681.

Impact of prior SARS-CoV-2 infection on postoperative recovery in patients with hepatocellular carcinoma resection.

Fang D, Wu L, Gan B, Guo C, Chen Z, Zhou S BMC Gastroenterol. 2024; 24(1):317.

PMID: 39289600 PMC: 11409749. DOI: 10.1186/s12876-024-03412-7.

Histopathological impact of SARS-CoV-2 on the liver: Cellular damage and long-term complications.

Rodriguez-Espada A, Salgado-de la Mora M, Rodriguez-Paniagua B, Limon-de la Rosa N, Martinez-Gutierrez M, Pastrana-Brandes S World J Gastroenterol. 2024; 30(22):2866-2880.

PMID: 38947288 PMC: 11212712. DOI: 10.3748/wjg.v30.i22.2866.

Heatstroke Comorbid with SARS-CoV-2 Infection: A Case Report and Literature Review.

Ni X, Liu Z, Zeng Y, Liu Z Int Med Case Rep J. 2024; 17:555-563.

PMID: 38831931 PMC: 11146621. DOI: 10.2147/IMCRJ.S461078.

Interplay of Demographic Influences, Clinical Manifestations, and Longitudinal Profile of Laboratory Parameters in the Progression of SARS-CoV-2 Infection: Insights from the Saudi Population.

Al-Hassinah S, Al-Daihan S, Alahmadi M, Alghamdi S, Almulhim R, Obeid D Microorganisms. 2024; 12(5).

PMID: 38792852 PMC: 11124088. DOI: 10.3390/microorganisms12051022.

References

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

Wang Y, Wang Y, Luo W, Huang L, Xiao J, Li F . A comprehensive investigation of the mRNA and protein level of ACE2, the putative receptor of SARS-CoV-2, in human tissues and blood cells. Int J Med Sci. 2020; 17(11):1522-1531. PMC: 7359402. DOI: 10.7150/ijms.46695. View

Zhang C, Shi L, Wang F . Liver injury in COVID-19: management and challenges. Lancet Gastroenterol Hepatol. 2020; 5(5):428-430. PMC: 7129165. DOI: 10.1016/S2468-1253(20)30057-1. View

Lamb Y . BNT162b2 mRNA COVID-19 Vaccine: First Approval. Drugs. 2021; 81(4):495-501. PMC: 7938284. DOI: 10.1007/s40265-021-01480-7. View

Scialo F, Daniele A, Amato F, Pastore L, Matera M, Cazzola M . ACE2: The Major Cell Entry Receptor for SARS-CoV-2. Lung. 2020; 198(6):867-877. PMC: 7653219. DOI: 10.1007/s00408-020-00408-4. View

Wu J, Liu J, Zhao X, Liu C, Wang W, Wang D . Clinical Characteristics of Imported Cases of Coronavirus Disease 2019 (COVID-19) in Jiangsu Province: A Multicenter Descriptive Study. Clin Infect Dis. 2020; 71(15):706-712. PMC: 7108195. DOI: 10.1093/cid/ciaa199. View

Weiss S, Navas-Martin S . Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4):635-64. PMC: 1306801. DOI: 10.1128/MMBR.69.4.635-664.2005. View

Ibanez-Samaniego L, Bighelli F, Uson C, Caravaca C, Carrillo C, Romero M . Elevation of Liver Fibrosis Index FIB-4 Is Associated With Poor Clinical Outcomes in Patients With COVID-19. J Infect Dis. 2020; 222(5):726-733. PMC: 7337860. DOI: 10.1093/infdis/jiaa355. View

Amiri-Dashatan N, Koushki M, Ghorbani F, Naderi N . Increased inflammatory markers correlate with liver damage and predict severe COVID-19: a systematic review and meta-analysis. Gastroenterol Hepatol Bed Bench. 2020; 13(4):282-291. PMC: 7682967. View

10.

Cao B, Wang Y, Wen D, Liu W, Wang J, Fan G . A Trial of Lopinavir-Ritonavir in Adults Hospitalized with Severe Covid-19. N Engl J Med. 2020; 382(19):1787-1799. PMC: 7121492. DOI: 10.1056/NEJMoa2001282. View

11.

Ji D, Qin E, Xu J, Zhang D, Cheng G, Wang Y . Non-alcoholic fatty liver diseases in patients with COVID-19: A retrospective study. J Hepatol. 2020; 73(2):451-453. PMC: 7141624. DOI: 10.1016/j.jhep.2020.03.044. View

12.

Wang Y, Liu S, Liu H, Li W, Lin F, Jiang L . SARS-CoV-2 infection of the liver directly contributes to hepatic impairment in patients with COVID-19. J Hepatol. 2020; 73(4):807-816. PMC: 7211738. DOI: 10.1016/j.jhep.2020.05.002. View

13.

Ali F, Mohammedsaleh Z, Ali M, Ghogar O . Impact of cytokine storm and systemic inflammation on liver impairment patients infected by SARS-CoV-2: Prospective therapeutic challenges. World J Gastroenterol. 2021; 27(15):1531-1552. PMC: 8058655. DOI: 10.3748/wjg.v27.i15.1531. View

14.

Ahn J, Kim J, Hong S, Choi S, Yang M, Ju Y . Nasal ciliated cells are primary targets for SARS-CoV-2 replication in the early stage of COVID-19. J Clin Invest. 2021; 131(13). PMC: 8245175. DOI: 10.1172/JCI148517. View

15.

Voysey M, Clemens S, Madhi S, Weckx L, Folegatti P, Aley P . Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397(10269):99-111. PMC: 7723445. DOI: 10.1016/S0140-6736(20)32661-1. View

16.

Arabi Y, Fowler R, Hayden F . Critical care management of adults with community-acquired severe respiratory viral infection. Intensive Care Med. 2020; 46(2):315-328. PMC: 7079862. DOI: 10.1007/s00134-020-05943-5. View

17.

Page E, Ariens R . Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb Res. 2021; 200:1-8. PMC: 7813504. DOI: 10.1016/j.thromres.2021.01.005. View

18.

Sadoff J, Gray G, Vandebosch A, Cardenas V, Shukarev G, Grinsztejn B . Safety and Efficacy of Single-Dose Ad26.COV2.S Vaccine against Covid-19. N Engl J Med. 2021; 384(23):2187-2201. PMC: 8220996. DOI: 10.1056/NEJMoa2101544. View

19.

Rosser B, Gores G . Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology. 1995; 108(1):252-75. DOI: 10.1016/0016-5085(95)90032-2. View

20.

Lagana S, Kudose S, Iuga A, Lee M, Fazlollahi L, Remotti H . Hepatic pathology in patients dying of COVID-19: a series of 40 cases including clinical, histologic, and virologic data. Mod Pathol. 2020; 33(11):2147-2155. PMC: 7424245. DOI: 10.1038/s41379-020-00649-x. View